Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...
19hon MSN
In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...
Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight ...
The negotiated prices of 15 Medicare Part D drugs, which include several blockbusters, will go into effect in 2027.
Variant Bio, a small biotech company based in Seattle, is using genetic information from Indigenous people to develop drugs ...
In the final days of the Biden administration, the U.S. Department of Health and Human Services’ Centers for Medicare and ...
In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price ...
In a report released yesterday, Jasper Hellweg from Argus Research maintained a Buy rating on Novo Nordisk (NVO – Research Report). The ...
Novo Nordisk also boasted a 55.6% share of the GLP-1 drug space, compared to 54.4% as of August 2023. The company's most famous brands, Wegovy and Ozempic, are both GLP-1s.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback